The Allergy Profile of Hyaluronic Acid: Why Is the Risk So Low?
Hyaluronic acid (HA) is a glycosaminoglycan molecule naturally present in the human body. It is found abundantly in joints, ocular fluid and subcutaneous tissue. For this reason, the body does not recognise HA as "foreign" and the tendency to mount an immune response is extremely low.
The HA used in modern dermatological filler products can be derived from two different sources:
- Animal-derived HA (pre-biofermentation): Historically obtained from rooster combs or animal eyes. Now largely abandoned; allergy risk was relatively higher (1–2%).
- Non-Animal Stabilized Hyaluronic Acid (NASHA) — Biofermentation: Produced by controlled fermentation of Streptococcus equi bacteria. Contains no animal protein residues. Allergy risk is 0.02–0.4%. Leading brands such as Juvederm, Restylane and Teoxane use this technology.
With the widespread adoption of NASHA technology, international dermatology and aesthetic surgery guidelines have clearly stated that routine allergy testing is unnecessary.
Why Is Routine Allergy Testing Not Recommended?
NICE (National Institute for Health and Care Excellence) guidelines and British Journal of Dermatology position statements do not recommend routine skin testing for NASHA fillers for the following reasons:
- False negatives: Skin testing cannot predict a true allergy 100% of the time.
- False positives: Mechanical irritation at the application site, physical stimulus or a lidocaine reaction may give false positive results.
- Test timing problem: A classic intradermal test is read at 20–30 minutes; however, delayed hypersensitivity reactions (Type IV) occur days later — routine testing cannot detect these.
- Risk-benefit balance: The injection during the test itself carries its own complication risk, while the benefit is extremely limited.
True HA Allergy vs Late Inflammatory Reaction: The Critical Difference
Not all reactions occurring after filler are true allergies. This distinction is very important for both patient management and appropriate treatment selection:
| Reaction Type | Onset Time | Symptoms | Treatment |
|---|---|---|---|
| Immediate allergic reaction (IgE-mediated) | Within minutes | Urticaria, angioedema, sometimes anaphylaxis | Epinephrine, antihistamine, corticosteroid |
| Delayed hypersensitivity (Type IV) | 2–4 days later | Redness, swelling, itching, firmness | Topical/systemic steroid, antihistamine |
| Biofilm infection | Weeks–months later | Recurring swelling, redness episodes | Antibiotics (macrolide/tetracyclines) ± hyaluronidase |
| Foreign body granuloma | Months–years later | Hard nodules, chronic inflammation | Intralesional steroid, hyaluronidase, occasionally surgery |
| Vascular occlusion | Within minutes–hours | Blanching/livedo, severe pain, ischaemia | EMERGENCY: Hyaluronidase, warm compress, aspirin |
Lidocaine Allergy: The Real Risk Factor in Fillers
The majority of modern filler products come with lidocaine (local anaesthetic) added to the formulation to increase procedural comfort (e.g. Juvederm Ultra Plus XC, Restylane Lyft with Lidocaine). This situation brings reactions to lidocaine rather than HA itself to the fore.
Lidocaine reactions can be of two types:
- True lidocaine allergy (IgE-mediated): Rare but serious. Can be confirmed with skin test or provocation test.
- Toxic/pharmacological response: Occurs with excessive dose or intravascular injection; may include perioral numbness, tinnitus, dizziness.
In patients with a history of reaction to aminoamide group (lidocaine, mepivacaine, bupivacaine) local anaesthetics, a lidocaine-free filler formulation should be preferred or an allergy consultation should be requested.
High-Risk Profiles: Situations Requiring Additional Evaluation
Although routine allergy testing is not recommended, more careful medical history and consultation when necessary is required in the following situations:
- Beeswax allergy: Some older filler formulations contained beeswax; negligible today but noted.
- Severe animal protein allergy (eggs, fish, etc.): Theoretical risk with NASHA technology is very low but noted.
- Autoimmune disease (Lupus, Sjögren's, RA): Risk of granuloma and late inflammation is elevated due to immune system activation.
- Previous filler reaction: The type, timing and brand of the reaction is recorded and evaluated.
- Active autoimmune flare: Absolute postponement criterion.
- Systemic corticosteroid or immunosuppressive therapy: Immune response may be altered; infection risk increases.
Pre-Filler Safety Protocol: Steps That Supersede Allergy Testing
The following protocol steps are sufficient and necessary for safe filler application without requiring an allergy test:
- Comprehensive medical history: All medications, allergies, autoimmune diseases, previous filler experience are reviewed.
- Product information sharing: The contents of the filler to be used (HA concentration, crosslinking density, presence of lidocaine) are explained to the patient.
- Consent form: Possible complications (swelling, bruising, infection, granuloma, vascular complication, rarely anaphylaxis) and emergency intervention information are conveyed in writing.
- Asepsis: Wide-field skin preparation and sterile injection technique.
- Minimally invasive approach: Increased cannula preference, slow and aspirating needle technique.
- Emergency equipment readiness: Must be present at all times (listed below).
Mandatory Clinic Emergency Equipment
Every clinic performing filler must have the following emergency equipment available (per BCAM and ISAPS guidelines):
- Epinephrine (Adrenaline) 1:1000 ampoule: For anaphylaxis. Intramuscular administration instructions must be ready.
- Hyaluronidase (Hylase): For vascular occlusion and overfilling. Diluted and prepared in ready form.
- Antihistamine (IV/IM): For allergic reaction management.
- Systemic corticosteroid (IV/IM): For severe hypersensitivity.
- Aspirin (300 mg): For vascular complication protocol.
- Defibrillator or AED: Mandatory in accredited clinics.
The absence of this equipment is a serious safety deficiency for a clinic. It is the patient's right to ask about the clinic's emergency equipment before undergoing filler treatment.
Frequently Asked Questions
I previously had filler with no reaction; can I have it again? Not having had problems in previous applications is generally a good sign. However, each application carries its own risk; if the product brand or formulation has changed, let your physician know.
Where can I get an allergy test? Routine testing for hyaluronic acid fillers is not recommended by guidelines. If you have a suspected lidocaine allergy, specific skin tests and provocation tests can be performed at an allergy clinic.
I had swelling and redness after filler — is this an allergy? Swelling and mild redness in the first 3–7 days after injection is completely normal. If the reaction persists beyond 10 days, pain is increasing, or new lesions are appearing, contact your physician.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.